Cholesterol and chronic hepatitis C virus infection

Hepatology Research

Volumn 41, Issue 8, 2011, Pages 697-710

  Honda, Akira ^a   Matsuzaki, Yasushi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cholesterol; Hepatitis C; HMG CoA reductase; Hypocholesterolemia; Statins; Steatosis

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; CORE PROTEIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPARAN SULFATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN; PEGINTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPID; RIBAVIRIN; TETRASPANIN; VERY LOW DENSITY LIPOPROTEIN; VIRUS RNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DECISION TREE; DOWN REGULATION; DRUG EFFICACY; ENDOPLASMIC RETICULUM; FATTY ACID OXIDATION; GENE AMPLIFICATION; GENE LOCUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOCHOLESTEROLEMIA; INHIBITION KINETICS; INSULIN RESISTANCE; LIFE CYCLE; LIPID TRANSPORT; LIPOGENESIS; LIVER FIBROSIS; MOLECULAR WEIGHT; NONHUMAN; OSMOLARITY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; THROMBOCYTE COUNT; VIRION; VIROGENESIS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS REPLICATION;

EID: 79960730520     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00838.x     Document Type: Review

References (164)

1. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog 2007; 3: 1017-22.
2. Ogawa K, Hishiki T, Shimizu Y etal. Hepatitis C virus utilizes lipid droplet for production of infectious virus. Proc Jpn Acad Ser B 2009; 85: 217-28.
3. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2009; 21: 33-40.
4. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29: 26-37.
5. Razin S. Cholesterol incorporation into bacterial membranes. J Bacteriol 1975; 124: 570-2.
6. Lenard J, Compans RW. The membrane structure of lipid-containing viruses. Biochim Biophys Acta 1974; 344: 51-94.
7. Sun X, Whittaker GR. Role for influenza virus envelope cholesterol in virus entry and infection. J Virol 2003; 77: 12543-51.
8. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-13.
9. Wakita T, Pietschmann T, Kato T etal. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
10. Zhong J, Gastaminza P, Cheng G etal. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9.
11. Lindenbach BD, Evans MJ, Syder AJ etal. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
12. Aizaki H, Morikawa K, Fukasawa M etal. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 2008; 82: 5715-24.
13. Shinitzky M, Inbar M. Microviscosity parameters and protein mobility in biological membranes. Biochim Biophys Acta 1976; 433: 133-49.
14. Miyanari Y, Atsuzawa K, Usuda N etal. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-97.
15. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with β-lipoprotein. Med Microbiol Immunol 1992; 181: 293-300.
16. Andre P, Komurian-Pradel F, Deforges S etal. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-28.
17. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-28.
18. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-71.
19. Owen DM, Huang H, Ye J, Gale M Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99-108.
20. Monazahian M, Kippenberger S, Muller A etal. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol 2000; 188: 177-84.
21. Cladaras C, Hadzopoulou-Cladaras M, Nolte RT, Atkinson D, Zannis VI. The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. EMBO J 1986; 5: 3495-507.
22. Tanaka E, Ohue C, Aoyagi K etal. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that ofgenomic amplification of HCV RNA. Hepatology 2000; 32: 388-93.
23. Sasase N, Kim SR, Kim KI etal. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b. Intervirology 2008; 51 (Suppl 1): 70-5.
24. Kaito M, Watanabe S, Tsukiyama-Kohara K etal. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 1994; 75: 1755-60.
25. Nielsen SU, Bassendine MF, Martin C etal. Characterization of hepatitis C RNA-containing particles from human liver by density and size. J Gen Virol 2008; 89: 2507-17.
26. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002; 277: 17377-80.
27. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003; 44: 22-32.
28. Shelness GS, Ledford AS. Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly. Curr Opin Lipidol 2005; 16: 325-32.
29. Huang H, Sun F, Owen DM etal. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007; 104: 5848-53.
30. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008; 82: 2120-9.
31. Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007; 81: 13783-93.
32. Jiang J, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol 2009; 83: 12680-91.
33. Nahmias Y, Goldwasser J, Casali M etal. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 2008; 47: 1437-45.
34. Hishiki T, Shimizu Y, Tobita R etal. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol 2010; 84: 12048-57.
35. von Hahn T, Rice CM. Hepatitis C virus entry. J Biol Chem 2008; 283: 3689-93.
36. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008; 10: 821-7.
37. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009; 90: 1055-70.
38. Scarselli E, Ansuini H, Cerino R etal. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-25.
39. Barth H, Schafer C, Adah MI etal. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 41003-12.
40. Van Eck M, Hoekstra M, Out R etal. Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J Lipid Res 2008; 49: 136-46.
41. Pileri P, Uematsu Y, Campagnoli S etal. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
42. Evans MJ, von Hahn T, Tscherne DM etal. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-5.
43. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 2009; 83: 2011-14.
44. Ploss A, Evans MJ, Gaysinskaya VA etal. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-6.
45. Pietschmann T. Virology: Final entry key for hepatitis C. Nature 2009; 457: 797-8.
46. Maggi G, Bottelli R, Gola D etal. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996; 28: 436-40.
47. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997; 261: 159-65.
48. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.
49. Hofer H, Bankl HC, Wrba F etal. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880-5.
50. Petit JM, Benichou M, Duvillard L etal. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003; 98: 1150-4.
51. Moriya K, Shintani Y, Fujie H etal. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 2003; 25: 371-6.
52. Siagris D, Christofidou M, Theocharis GJ etal. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13: 56-61.
53. Marzouk D, Sass J, Bakr I etal. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56: 1105-10.
54. Dai CY, Chuang WL, Ho CK etal. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008; 49: 9-16.
55. Hsu CS, Liu CJ, Liu CH etal. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int 2008; 2: 250-7.
56. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-32.
57. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009; 50: 1030-7.
58. Miyazaki T, Honda A, Ikegami T etal. HCV infection causes hypolipidemia regardless of hepatic damage or nutritional state-an epidemiological survey of a large Japanese cohort. Hepatol Res 2011; 41: 530-41.
59. Tada S, Saito H, Ebinuma H etal. Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. Hepatol Res 2009; 39: 195-9.
60. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157: 792-6.
61. Wang CC, Kao JH. Hepatitis C virus infection, lipids, and coronary heart disease: a Pandora's box. Hepatology 2010; 51: 343.
62. Chandler CE, Wilder DE, Pettini JL etal. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003; 44: 1887-901.
63. Cuchel M, Bloedon LT, Szapary PO etal. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356: 148-56.
64. Raal FJ, Santos RD, Blom DJ etal. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
65. Visser ME, Akdim F, Tribble DL etal. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010; 51: 1057-62.
66. Nakamuta M, Yada R, Fujino T etal. Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: a novel target for therapy? Int J Mol Med 2009; 24: 825-8.
67. Fujino T, Nakamuta M, Yada R etal. Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver. Hepatol Res 2010; 40: 923-9.
68. Gopal K, Johnson TC, Gopal S etal. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-40.
69. Martinez-Bauer E, Crespo J, Romero-Gomez M etal. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006; 43: 72-80.
70. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
71. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47.
72. Economou M, Milionis H, Filis S etal. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2008; 23: 586-91.
73. Ramcharran D, Wahed AS, Conjeevaram HS etal. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854-63.
74. Kurosaki M, Matsunaga K, Hirayama I etal. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010; 40: 251-60.
75. Kurosaki M, Sakamoto N, Iwasaki M etal. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol 2011; 83: 445-52.
76. Kurosaki M, Tanaka Y, Nishida N etal. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-48.
77. Enomoto N, Sakuma I, Asahina Y etal. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-30.
78. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
79. Kurosaki M, Enomoto N, Murakami T etal. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-b therapy. Hepatology 1997; 25: 750-3.
80. Munoz de Rueda P, Casado J, Paton R etal. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol 2008; 82: 6644-53.
81. Shirakawa H, Matsumoto A, Joshita S etal. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-60.
82. Ikeda H, Suzuki M, Okuse C etal. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res 2009; 39: 753-9.
83. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-80.
84. Akuta N, Suzuki F, Hirakawa M etal. A matched case-controlled study of 48 and 72weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-8.
85. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
86. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
87. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
88. Li JH, Lao XQ, Tillmann HL etal. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 1904-11.
89. Chayama K, Hayes CN, Yoshioka K etal. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. Hepatol Res 2010; 40: 1155-67.
90. Petit JM, Minello A, Duvillard L etal. Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load. Am J Physiol Endocrinol Metab 2007; 293: E416-20.
91. Meunier JC, Engle RE, Faulk K etal. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005; 102: 4560-5.
92. Cross TJ, Rashid MM, Berry PA, Harrison PM. The importance of steatosis in chronic hepatitis C infection and its management: A review. Hepatol Res 2010; 40: 237-47.
93. Moriya K, Yotsuyanagi H, Shintani Y etal. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78: 1527-31.
94. Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol Res 2009; 40: 69-82.
95. Shintani Y, Fujie H, Miyoshi H etal. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
96. Perlemuter G, Sabile A, Letteron P etal. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-94.
97. Moriishi K, Mochizuki R, Moriya K etal. Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad. Sci USA 2007; 104: 1661-6.
98. Yamaguchi A, Tazuma S, Nishioka T etal. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005; 50: 1361-71.
99. Dharancy S, Malapel M, Perlemuter G etal. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-42.
100. Oem JK, Jackel-Cram C, Li YP etal. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol 2008; 89: 1225-30.
101. Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem 2009; 284: 9237-46.
102. Woodhouse SD, Narayan R, Latham S etal. Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. Hepatology 2010; 52: 443-53.
103. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007; 81: 8122-30.
104. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637-59.
105. Hirayama T, Honda A, Matsuzaki Y etal. Hypercholesterolemia in rats with hepatomas: increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol. Hepatology 2006; 44: 602-11.
106. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-40.
107. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad. Sci USA 1999; 96: 11041-8.
108. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
109. Guan G, Jiang G, Koch RL, Shechter I. Molecular cloning and functional analysis of the promoter of the human squalene synthase gene. J Biol Chem 1995; 270: 21958-65.
110. Powell EE, Kroon PA. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. J Clin Invest 1994; 93: 2168-74.
111. Rudling M, Angelin B, Stahle L etal. Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7α-hydroxylase mRNAs in human liver. J Clin Endocrinol Metab 2002; 87: 4307-13.
112. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46.
113. Tian L, Song Y, Xing M etal. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 2010; 52: 1401-9.
114. Ikegami T, Honda A, Nakamuta M etal. Non-invasive measurement of cholesterol metabolism in patients with HCV infection by using serum marker sterols. Hepatology 2009; 50: 946A-947A. (Abstract).
115. Kato J, Kato N, Yoshida H, Ono-Nita SK, Shiratori Y, Omata M. Hepatitis C virus NS4A and NS4B proteins suppress translation in vivo. J Med Virol 2002; 66: 187-99.
116. Florese RH, Nagano-Fujii M, Iwanaga Y, Hidajat R, Hotta H. Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res 2002; 90: 119-31.
117. DeBose-Boyd RA. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 2008; 18: 609-21.
118. Kawaguchi T, Yoshida T, Harada M etal. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508.
119. Miyamoto H, Moriishi K, Moriya K etal. Involvement of the PA28γ-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol 2007; 81: 1727-35.
120. Kasai D, Adachi T, Deng L etal. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol 2009; 50: 883-94.
121. Gibson DM, Parker RA, Stewart CS, Evenson KJ. Short-term regulation of hydroxymethylglutaryl coenzyme A reductase by reversible phosphorylation: modulation of reductase phosphatase in rat hepatocytes. Adv Enzyme Regul 1982; 20: 263-83.
122. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-25.
123. Delang L, Paeshuyse J, Vliegen I etal. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50: 6-16.
124. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003; 100: 15865-70.
125. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102: 2561-6.
126. Wang C, Gale M Jr, Keller BC etal. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005; 18: 425-34.
127. Lerner EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995; 270: 26770-3.
128. Bader T, Fazili J, Madhoun M etal. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103: 1383-9.
129. Milazzo L, Meroni L, Galazzi M etal. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat 2009; 16: 479-84.
130. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007; 45: 895-8.
131. Forde KA, Law C, O'Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009; 15: 5020-7.
132. Patel K, Jhaveri R, George J etal. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J Viral Hepat 2011; 18: 331-7.
133. Sezaki H, Suzuki F, Akuta N etal. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009; 52: 43-8.
134. Milazzo L, Caramma I, Mazzali C etal. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother 2010; 65: 735-40.
135. Williams ML, Menon GK, Hanley KP. HMG-CoA reductase inhibitors perturb fatty acid metabolism and induce peroxisomes in keratinocytes. J Lipid Res 1992; 33: 193-208.
136. Fujioka T, Tsujita Y, Shimotsu H. Induction of fatty acid synthesis by pravastatin sodium in rat liver and primary hepatocytes. Eur J Pharmacol 1997; 328: 235-9.
137. Roglans N, Verd JC, Peris C etal. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 2002; 37: 445-54.
138. Forman BM, Ruan B, Chen J, Schroepfer GJ Jr, Evans RM. The orphan nuclear receptor LXRα is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 1997; 94: 10588-93.
139. Gan X, Kaplan R, Menke JG etal. Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem 2001; 276: 48702-8.
140. Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag 2008; 4: 131-41.
141. Fujita N, Kaito M, Kai M etal. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006; 13: 441-8.
142. Stahlberg D, Reihner E, Ewerth S, Einarsson K, Angelin B. Effects of bezafibrate on hepatic cholesterol metabolism. Eur J Clin Pharmacol 1991; 40 (Suppl 1): S33-6.
143. Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res 2009; 50 (Suppl): S15-27.
144. Gill S, Chow R, Brown AJ. Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Prog Lipid Res 2008; 47: 391-404.
145. Song BL, Javitt NB, DeBose-Boyd RA. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metab 2005; 1: 179-89.
146. Sever N, Song BL, Yabe D, Goldstein JL, Brown MS, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem 2003; 278: 52479-90.
147. Su AI, Pezacki JP, Wodicka L etal. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99: 15669-74.
148. Sagan SM, Rouleau Y, Leggiadro C etal. The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication. Biochem Cell Biol 2006; 84: 67-79.
149. Pezacki JP, Sagan SM, Tonary AM etal. Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol 2009; 9: 2. [Cited 11 Jun 2011.] Available from URL.
150. Omura S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev 1976; 40: 681-97.
151. Cenedella RJ. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 2009; 44: 477-87.
152. Takano T, Tsukiyama-Kohara K, Hayashi M etal. Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes. J Hepatol 2011 [Epub ahead of print].
153. Honda A, Yamashita K, Miyazaki H etal. Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. J Lipid Res 2008; 49: 2063-73.
154. Honda A, Yamashita K, Ikegami T etal. Highly sensitive quantification of serum malonate, a possible marker for de novo lipogenesis, by LC-ESI-MS/MS. J Lipid Res 2009; 50: 2124-30.
155. Honda A, Yamashita K, Hara T etal. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res 2009; 50: 350-7.
156. Leu GZ, Lin TY, Hsu JT. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun 2004; 318: 275-80.
157. Zaima N, Sugawara T, Goto D, Hirata T. Trans geometric isomers of EPA decrease LXRα-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1β. J Lipid Res 2006; 47: 2712-17.
158. Chen CK, Hudock MP, Zhang Y etal. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem 2008; 51: 5594-607.
159. Hiyoshi H, Yanagimachi M, Ito M etal. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J Lipid Res 2003; 44: 128-35.
160. 7-reductase: substrate specificity, competitive and non-competitive inhibition, and phosphorylation/dephosphorylation. J Lipid Res 1998; 39: 2471-6.
161. Honda A, Tint GS, Shefer S, Batta AK, Honda M, Salen G. Effect of YM 9429, a potent teratogen, on cholesterol biosynthesis in cultured cells and rat liver microsomes. Steroids 1996; 61: 544-8.
162. Zhang Y, Lee FY, Barrera G etal. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad. Sci USA 2006; 103: 1006-11.
163. Chao F, Gong W, Zheng Y etal. Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte. Atherosclerosis 2010; 213: 443-8.
164. Sepe V, Bifulco G, Renga B, D'Amore C, Fiorucci S, Zampella A. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid X receptor. J Med Chem 2011; 54: 1314-20.